

Guideline Page and Request	Panel Discussion/References	Institution Vote			
		YES	NO	ABSTAIN	ABSENT
<p>BONE-B Internal request: Upon review, panel member notes that higher-level evidence for several of the regimens listed on our Systemic Therapy page was available, potentially warranting a change from category 2A to category 1 for VAC/IE (Ewing sarcoma); methotrexate/cisplatin/doxorubicin (osteosarcoma); and cisplatin/doxorubicin (osteosarcoma)</p>	<p>Upon review of the data in the noted reference(s), the panel consensus was to change first-line therapy with VAC/IE to a category 1 recommendation for Ewing sarcoma.</p> <p>Grier, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348:694-701. https://www.ncbi.nlm.nih.gov/pubmed/12594313</p> <p>Womer, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: A report from the Children's Oncology Group. J Clin Oncol 2012 Nov 20;30(33):4148-54. https://www.ncbi.nlm.nih.gov/pubmed/23091096</p>	13	1	4	9
	<p>Upon review of the data in the noted reference(s), the panel consensus was to change first-line therapy with cisplatin/doxorubicin to a category 1 recommendation for osteosarcoma.</p> <p>Lewis, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 2007;99:112-128. https://www.ncbi.nlm.nih.gov/pubmed/17227995</p> <p>Souhami RL, Craft AW, Van der Eijken JW, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 1997;350:911-917. https://www.ncbi.nlm.nih.gov/pubmed/9314869</p>	12	0	6	9
	<p>Upon review of the data in the noted reference(s), the panel consensus was to change first-line therapy with high-dose methotrexate/cisplatin/doxorubicin to a category 1 recommendation for osteosarcoma.</p> <p>Bacci G, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol 2000;18:4016-4027. https://www.ncbi.nlm.nih.gov/pubmed/11118462</p>	12	1	5	9

	<p>Winkler, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 1988;6:329-337. https://www.ncbi.nlm.nih.gov/pubmed/2448428</p> <p>Bacci G, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol 2003;14:1126-1134. https://www.ncbi.nlm.nih.gov/pubmed/12853357</p> <p>Marina NM et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EUARMOS-1): an open-label, international, randomized controlled trial. Lancet Oncol 2016;17:1396-408. https://www.ncbi.nlm.nih.gov/pubmed/27569442</p>				
--	--	--	--	--	--